The serotonin syndrome scale: first results on validity

Area of Science:

• Neuroscience
• Psychiatry
• Clinical Pharmacology

Background:

• The serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity.
• Existing diagnostic criteria for serotonin syndrome lack operationalization for assessing severity.
• Paroxetine, a selective serotonin reuptake inhibitor (SSRI), is commonly used to treat depression and can increase serotonin levels.

Purpose of the Study:

• To develop and validate the Serotonin Syndrome Scale (SSS) for objective assessment of serotonin syndrome.
• To evaluate the relationship between the SSS, paroxetine plasma levels, and loudness dependence of auditory evoked potentials (LDAEP) in patients treated with paroxetine.

Main Methods:

• Development of the Serotonin Syndrome Scale (SSS) based on Sternbach's diagnostic criteria.
• Investigated correlations between SSS scores and paroxetine plasma levels in 42 depressed patients.
• Assessed the relationship between SSS scores and LDAEP in 24 depressed patients, where strong LDAEP indicates low central serotonergic neurotransmission.

Main Results:

• The SSS demonstrated a positive correlation with paroxetine plasma levels.
• The SSS showed a negative correlation with LDAEP, supporting its validity.
• Using an SSS cutoff > 6, mild serotonin syndromes were identified in 5 out of 42 patients.

Conclusions:

• The Serotonin Syndrome Scale (SSS) is a valid and potentially useful tool for assessing the presence and severity of serotonin syndrome.
• The SSS can aid clinicians and researchers in diagnosing and managing serotonin syndrome.
• The scale's findings support the link between SSRI treatment, serotonin syndrome symptoms, and central serotonergic activity.